

Supporting Information

Experimental and theoretical investigations of cyclometalated ruthenium(II) complex containing CCC-pincer and anti-inflammatory drugs as ligands: synthesis, characterization, inhibition of cyclooxygenase and in vitro cytotoxicity activities on cancer cell lines

Leila Tabrizi ^{1*†}, Lukman O. Olasunkanmi ^{2,3*†}, Olatomide A. Fadare ²

¹ School of Chemistry, National University of Ireland, Galway, University Road, Galway, Ireland

² Department of Chemistry, Faculty of Science, Obafemi Awolowo University, Ile-Ife 220005, Nigeria.

³ Material Science Innovation and Modelling (MaSIM) Research Focus Area, Faculty of Natural and Agricultural Sciences, North-West University (Mafikeng Campus), Private Bag X2046, Mmabatho, South Africa

Corresponding author: Leila Tabrizi; Email: LEILA.TABRIZI@nuigalway.ie

Corresponding author: Lukman O. Olasunkanmi; Email: waleolasunkanmi@gmail.com





Figure S1. ¹H NMR spectrum of ligand **1** (DMSO-*d*₆).






Figure S3. ^1H NMR spectrum of complex **3** ($\text{DMSO-}d_6$).




Figure S4. ¹³C NMR spectrum of ligand **1** (DMSO-*d*₆).




Figure S5. ^{13}C NMR spectrum of ligand **2** ($\text{DMSO}-d_6$).




Figure S6. ^{13}C NMR spectrum of complex **3** ($\text{DMSO-}d_6$).




Figure S7. ^{31}P NMR spectrum of complex **3** ($\text{DMSO-}d_6$).




Figure S8. TOF MS spectrum of ligand 1.




Figure S9. TOF MS spectrum of ligand 2.




Figure S10. TOF MS spectrum of complex **3**.




Figure S11. HPLC chromatogram of the complex **3** in PBS/DMSO (1%) solution before (0h) and after incubation time (72h) at 37 °C.